Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
Autore:
Chanson, P; Boerlin, V; Ajzenberg, C; Bachelot, Y; Benito, P; Bringer, J; Caron, P; Charbonnel, B; Cortet, C; Delemer, B; Escobar-Jimenez, F; Foubert, L; Gaztambide, S; Jockenhoevel, F; Kuhn, JM; Leclere, J; Lorcy, Y; Perlemuter, L; Prestele, H; Roger, P; Rohmer, V; Santen, R; Sassolas, G; Scherbaum, WA; Schopohl, J; Torres, E; Varela, C; Villamil, F; Webb, SM;
Indirizzi:
CHU Bicetre, Serv Endocrinol & Malad Reprod, F-94275 Le Kremlin Bicetre, France CHU Bicetre Le Kremlin Bicetre France F-94275 Le Kremlin Bicetre, France Novartis Pharma AG, Clin Res & Dev, Basel, Switzerland Novartis Pharma AGBasel Switzerland Clin Res & Dev, Basel, Switzerland Hop Lariboisiere, F-75475 Paris, France Hop Lariboisiere Paris France F-75475 ariboisiere, F-75475 Paris, France Hop La Pitie Salpetriere, Paris, France Hop La Pitie Salpetriere Paris France Pitie Salpetriere, Paris, France CHU Grenoble, F-38043 Grenoble, France CHU Grenoble Grenoble France F-38043 Grenoble, F-38043 Grenoble, France Hop Lapeyronie, Montpellier, France Hop Lapeyronie Montpellier FranceHop Lapeyronie, Montpellier, France CHU Rangueil, F-31054 Toulouse, France CHU Rangueil Toulouse France F-31054 Rangueil, F-31054 Toulouse, France Hotel Dieu, Nantes, France Hotel Dieu Nantes FranceHotel Dieu, Nantes, France Ctr Hosp Reg & Univ Lille, F-59037 Lille, France Ctr Hosp Reg & Univ Lille Lille France F-59037 le, F-59037 Lille, France Hop Maison Blanche, Reims, France Hop Maison Blanche Reims FranceHop Maison Blanche, Reims, France Hop Bois Guillaume, Bois Guillaume, France Hop Bois Guillaume Bois Guillaume France llaume, Bois Guillaume, France Hop Brabois, Vandoeuvre Nancy, France Hop Brabois Vandoeuvre Nancy France p Brabois, Vandoeuvre Nancy, France Hop Sud, Rennes, France Hop Sud Rennes FranceHop Sud, Rennes, France Ctr Hosp Henri Mondor, Creteil, France Ctr Hosp Henri Mondor Creteil France Hosp Henri Mondor, Creteil, France Hop Haut Leveque, Pessac, France Hop Haut Leveque Pessac FranceHop Haut Leveque, Pessac, France Ctr Hosp Reg & Univ, Angers, France Ctr Hosp Reg & Univ Angers FranceCtr Hosp Reg & Univ, Angers, France Hop Neurocardiol, Lyon, France Hop Neurocardiol Lyon FranceHop Neurocardiol, Lyon, France Univ Klin Koln, Klin & Poliklin Innere Med 2, Cologne, Germany Univ Klin Koln Cologne Germany Poliklin Innere Med 2, Cologne, Germany Univ Klin Dusseldorf, Dusseldorf, Germany Univ Klin Dusseldorf Dusseldorf Germany Dusseldorf, Dusseldorf, Germany LMU, Klinikum Innenstadt, Med Klin, Munich, Germany LMU Munich GermanyLMU, Klinikum Innenstadt, Med Klin, Munich, Germany Hosp Reina Sofia, Cordoba, Spain Hosp Reina Sofia Cordoba SpainHosp Reina Sofia, Cordoba, Spain Hosp Clin San Cecilio, Granada, Spain Hosp Clin San Cecilio Granada Spain sp Clin San Cecilio, Granada, Spain Hosp Cruces, Baracaldo, Spain Hosp Cruces Baracaldo SpainHosp Cruces, Baracaldo, Spain Hosp Ramon y Cajal, E-28034 Madrid, Spain Hosp Ramon y Cajal Madrid Spain E-28034 n y Cajal, E-28034 Madrid, Spain Hosp Univ Virgen Rocio, Dept Endocrinol, Seville, Spain Hosp Univ Virgen Rocio Seville Spain o, Dept Endocrinol, Seville, Spain Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain Hosp Santa Cruz & San Pablo Barcelona Spain E-08025 025 Barcelona, Spain
Titolo Testata:
CLINICAL ENDOCRINOLOGY
fascicolo: 5, volume: 53, anno: 2000,
pagine: 577 - 586
SICI:
0300-0664(200011)53:5<577:COOALA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-TERM TREATMENT; SLOW-RELEASE LANREOTIDE; GROWTH-HORMONE; SOMATOSTATIN; TOLERABILITY; PHARMACOKINETICS; EPIDEMIOLOGY; MULTICENTER; MANAGEMENT; BIM-23014;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Chanson, P CHU Bicetre, Serv Endocrinol & Malad Reprod, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France CHU Bicetre 78 Rue Gen Leclerc Le Kremlin Bicetre France F-94275
Citazione:
P. Chanson et al., "Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly", CLIN ENDOCR, 53(5), 2000, pp. 577-586

Abstract

BACKGROUND AND OBJECTIVE The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues. Long-acting depot formulations for intramuscular injection of two somatostatin analogues have recently become available: octreotide acetate LAR (Sandostatin(R) LAR(R), Novartis Pharma AG) and lanreotide SR (Somatuline(R), Ipsen Biotech). We wished to compare efficacy of octreotide LAR and lanreotide SR inacromegalic patients. PATIENTS AND METHODS A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26medical centres in France, Spain and Germany were studied. Before the study, all patients had been treated with intramuscular injections of lanreotide SR (mean duration, 26 months) at a dose of 30 mg which was injected every10 days in 64 and every 14 days in 61 patients, respectively. All patientswere switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months. In order to obtain efficacy and safety data of lanreotide SR under study conditions, it was decided to randomly assign at day 1, in a 3 : 1 ratio, the time point of the treatment switch; 27 of the patients were randomly assigned to continue the lanreotideSR treatment for the first 3 months of the study (group A); they were on octreotide LAR 20 mg from month 4-6. The other 98 patients were assigned to be switched to treatment with octreotide LAR 20 mg at day 1 (group B). In group B patients, octreotide LAR treatment was continued until month 6, withan adjustment of the dose based on GH levels obtained at month 3. RESULTS The mean GH concentration decreased from 9.6 +/- 1.3 mU/l at the last evaluation on lanreotide SR to 6.8 +/- 1.0 mU/l after three injections of octreotide LAR (P < 0.001). The percentages of patients with mean GH values less than or equal to 6.5 mU/l (2.5 mug/l) and less than or equal to 2.6 mU/l (1.0 mug/l) at the last evaluation on lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively. IGF-I levels were normal in 48% atthe last evaluation on lanreotide SR and in 65% after 3 months on octreotide LAR (P < 0.001). Patients with pre-study pituitary irradiation had lowermean GH and IGF-I concentrations. But the effects of the treatment change did not differ between the irradiated and the nonirradiated patients. In general both drugs were well tolerated. CONCLUSION Octreotide LAR 20 mg administered once monthly was more effective than lanreotide SR 30 mg administered 2 or 3 times monthly in reducing GH and IGF-I in patients with acromegaly.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 19:02:13